tiprankstipranks
Trending News
More News >

Protagenic Therapeutics Completes Acquisition of Phytanix Bio

Story Highlights
Protagenic Therapeutics Completes Acquisition of Phytanix Bio

Don’t Miss TipRanks’ Half-Year Sale

Protagenic Therapeutics ( (PTIX) ) has issued an announcement.

On May 15, 2025, Protagenic Therapeutics entered into a Share Exchange Agreement with Alterola Biotech and Phytanix Bio, resulting in the acquisition of Phytanix Bio’s shares. The transaction, completed on May 16, 2025, involves Protagenic issuing shares of common and preferred stock to Phytanix shareholders, forming a combined entity focused on neuropsychiatry and CNS disorders. This merger is expected to enhance Protagenic’s pipeline with new CNS programs and diversify its assets, integrating expertise from Phytanix’s team, which has experience with notable pharmaceuticals like Sativex and Epidiolex.

Spark’s Take on PTIX Stock

According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.

Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.

To see Spark’s full report on PTIX stock, click here.

More about Protagenic Therapeutics

Protagenic Therapeutics, Inc. is a company pioneering peptides for stress-related disorders, focusing on the development of neuroactive biopharmaceuticals. Phytanix Bio Inc. specializes in developing medicines from cannabinoid and ‘cannabinoid-like’ molecules.

Average Trading Volume: 461,230

Technical Sentiment Signal: Sell

Current Market Cap: $1.78M

For detailed information about PTIX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1